Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.

You may also be interested in...



Global Oncology Drug Sales Growth Is Highest Among Top 10 Treatment Classes

Oncology, lipid lowering and respiratory drugs helped to fuel 7 percent sales growth in the global pharmaceutical market in 2006, IMS reports.

Global Oncology Drug Sales Growth Is Highest Among Top 10 Treatment Classes

Oncology, lipid lowering and respiratory drugs helped to fuel 7 percent sales growth in the global pharmaceutical market in 2006, IMS reports.

Judge Rules Against Plavix Recall Based On Sanofi/Bristol’s Settlement Negotiations

Provisions included in a Plavix patent infringement settlement agreement between Sanofi-Aventis/Bristol-Myers Squibb and Apotex "foresaw the possibility that Apotex would launch a generic product and prohibited Sanofi from seeking injunctive relief for a specific period of time after the launch occurred," Manhattan Federal Judge Sidney Stein said in an Aug. 31 ruling, refusing to grant a recall of generic clopidogrel

Related Content

Topics

UsernamePublicRestriction

Register

PS065867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel